DERM Journey Medical Corp

Nasdaq journeymedicalcorp.com


$ 7.41 $ -0.11 (-1.46 %)    

Thursday, 16-Oct-2025 15:59:52 EDT
QQQ $ 598.41 $ 0.00 (0 %)
DIA $ 459.98 $ 0.00 (0 %)
SPY $ 660.25 $ 0.00 (0 %)
TLT $ 91.20 $ 0.00 (0 %)
GLD $ 396.95 $ 0.00 (0 %)
$ 7.4
$ 7.49
$ 7.04 x 50
$ 8.41 x 27
-- - --
$ 3.54 - $ 8.90
156,092
na
180.4M
$ 0.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-10-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-22-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 12-16-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 journey-medical-may-sell-3750000-shares-of-common-stock

-SEC Filing

 hc-wainwright--co-initiates-coverage-on-journey-medical-with-buy-rating-announces-price-target-of-13

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and ann...

 lake-street-maintains-buy-on-journey-medical-raises-price-target-to-13

Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to ...

 why-sapiens-international-shares-are-trading-higher-by-around-44-here-are-20-stocks-moving-premarket

Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday...

 journey-medical-q2-eps-016-misses-010-estimate-sales-15009m-beat-14933m-estimate

Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0...

 b-riley-securities-maintains-buy-on-journey-medical-raises-price-target-to-12

B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from...

 journey-medicals-emrosi-now-covered-for-65-of-us-commercial-lives-up-from-29-in-may

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025Expanding payer coverage supports ...

 journey-medical-to-join-russell-2000-and-russell-3000-indexes-effective-after-the-close-of-us-equity-markets-on-june-27-2025

Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"),...

 journey-medical-q1-eps-018-beats-024-estimate-sales-1314m-beat-1205m-estimate

Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.2...

 journey-medical-promotes-ramsey-alloush-currently-general-counsel-to-the-position-of-coo

Alloush Will Continue To Also Serve As The Company's General Counsel.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION